Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jul 14;6(7):1282-1288.
doi: 10.3889/oamjms.2018.290. eCollection 2018 Jul 20.

Key Issues in the Management of Multi-Drug Resistant Tuberculosis: A Case Report

Zorica Nanovic  1 , Biserka Kaeva-Jovkovska  2 , Gorica Breskovska  2 , Milena Petrovska  3
Affiliations
Case Reports

Key Issues in the Management of Multi-Drug Resistant Tuberculosis: A Case Report

Zorica Nanovic et al. Open Access Maced J Med Sci. .

Abstract

Background: Global tuberculosis (TB) epidemic is being driven to an increasing extent by the emergence and spread of drug-resistant strains of Mycobacterium tuberculosis complex (MTBC). We present a case of primary multidrug-resistant tuberculosis (MDR-TB), highlighting Macedonian MDR-TB management issues.

Case report: A 39-year old previously healthy Caucasian male, with no previous history of TB or close contact to TB, was admitted in referral TB-hospital due to respiratory bleeding. Chest X-ray revealed opacity with cavernous lesions in the right upper lobe. Sputum samples showed no presence of acid-fast bacilli (AFB) on fluorescence microscopy, but molecular tests (real-time PCR-based assay and multiplex PCR-based reverse hybridisation Line Probe Assay) confirmed the presence of MTBC, also revealing rifampicin and isoniazid resistance and absence of resistance to second-line anti-tubercular drugs. The strain was considered multidrug-resistant, lately confirmed by conventional methods in liquid and solid culture. Following the protocol of the World Health Organization, we started the longer treatment of MDR-TB comprised of at least five effective anti-tubercular drugs. Due to patient's extreme non-adherence, we had to delay and modify the regimen (i.e. omitting parenteral aminoglycoside) and to discharge him from the hospital a month after directly observed therapy (DOT) in negative pressure room. As there is no legal remedy in our country regarding involuntary isolation, our patient continued the regimen under ambulatory control of referral TB-hospital. Ignoring the risk of additional acquisition of drug resistance and prolonged exposure of the community to MDR-TB strain - for which he was repeatedly advised - he decided to cease the therapy six months after beginning.

Conclusion: The benefit of molecular tests in the early diagnosis of TB and drug resistance is unequivocal for adequate treatment of resistant forms of TB. Whole genome sequencing ensures additional knowledge of circulating strains and their resistance patterns. These are essentials of effective TB control programs and can provide evidence to medical and legal authorities for more active policies of screening, involuntary confinement and compliance with therapy, and alternative modalities for successful treatment, as a part of infection control.

Keywords: MDR-TB; MDR-TB treatment; Molecular tests for TB.

PubMed Disclaimer

Figures

Figure 1
Figure 1
At hospital admission, opacity with cavernous lesions in the right upper lobe
Figure 2
Figure 2
Timetable of therapy
Figure 3
Figure 3
Six months after cessation of treatment: opacity with cavernous lesions and fibrotic changes in the right upper lobe
See this image and copyright information in PMC

References

    1. Outhred AC, Jelfs P, Suliman B, Hill-Cawthorne GA, Crawford AB, Marais BJ, Sintchenko V. Added value of whole-genome sequencing for management of highly drug-resistant TB. Journal of Antimicrobial Chemotherapy. 2014;70(4):1198–202. https://doi.org/10.1093/jac/dku508. - PMC - PubMed
    1. Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ. Drug-resistant tuberculosis: time for visionary political leadership. The Lancet infectious diseases. 2013;13(6):529–39. https://doi.org/10.1016/S1473-3099(13)70030-6. - PubMed
    1. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact of multi-drug resistant TB outcomes. Eur Respir J. 2013;42(1):156–168. https://doi.org/10.1183/09031936.00134712 PMid:23100499 PMCid: PMC4487776. - PMC - PubMed
    1. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J. 2014;43(2):554–565. https://doi.org/10.1183/09031936.00079413 PMid:23949960. - PubMed
    1. Garrido MS, Talhari AC, Antunes IA, Matsuda JD, Zaranza ED, Martinez-Espinosa FE, Bührer-Sékula S. Primary multidrug-resistant tuberculosis and its control implications in the State of Amazonas, Brazil: report of 3 cases. Revista da Sociedade Brasileira de Medicina Tropical. 2012;45(4):530–2. https://doi.org/10.1590/S0037-86822012000400024 PMid:22930053. - PubMed

Publication types

LinkOut - more resources